Meanwhile, we found that breast cancer patients with ER+ status or higher SALL2 expression had longer disease‐free survival (DFS) and OS compared to breast cancer patients with ER− status or lower SALL2 expression (Fig 2C and D; Appendix Table S3). This evidence concerns the gene SALL2 and breast cancer.